GlassScriptPhysician profile
Joseph C Millin
NPI 1760484158
$4,582.84
in general payments reported to CMS, 2019-2025
35 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $573 · 2021: $682 · 2022: $475 · 2023: $787 · 2024: $983 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.16 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $525.93 | 2019-2025 | |
| Astellas Pharma US INC | $513.19 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $397.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $321.88 | 2020-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $313.12 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $309.16 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $270.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $219.68 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $189.65 | 2019-2021 | |
| Abbvie INC. | $178.03 | 2021-2023 | |
| Allergan, INC. | $173.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.15 | 2019-2021 | |
| Abbott Laboratories | $109.25 | 2021-2023 | Freestyle Libre 3 |
| Ge Healthcare | $107.27 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.10 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $100.27 | 2024 | Inspire |
| Lilly USA, LLC | $97.79 | 2021-2025 | Mounjaro, Kisunla |
| Dexcom, INC. | $56.05 | 2021-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $48.03 | 2023-2025 | Rexulti, Vyepti |
| Amarin Pharma, INC. | $47.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $42.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2023-2024 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $39.15 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $33.58 | 2021-2025 | Nexletol |
| Itamar Medical INC | $29.64 | 2023 | Watchpatone |
| Otsuka America Pharmaceutical, INC. | $23.40 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $21.57 | 2023 | Krystexxa |
| Biogen, INC. | $20.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.44 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $18.25 | 2021 | |
| Aimmune Therapeutics, INC. | $17.45 | 2024 | |
| Vertiflex, INC. | $16.63 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.12 | 2022 | |
| Redhill Biopharma INC. | $14.27 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.47 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Millin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.